Vigil Neuroscience, Inc.
VIGL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | -$0 |
| % Margin | – | – | 50% | – |
| R&D Expenses | $17 | $17 | $19 | $14 |
| G&A Expenses | $10 | $7 | $6 | $7 |
| SG&A Expenses | $10 | $7 | $6 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $27 | $23 | $25 | $21 |
| Operating Income | -$27 | -$23 | -$25 | -$21 |
| % Margin | – | – | -5,556.2% | – |
| Other Income/Exp. Net | $1 | $1 | $1 | $1 |
| Pre-Tax Income | -$27 | -$22 | -$24 | -$19 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$27 | -$22 | -$24 | -$19 |
| % Margin | – | – | -5,272.3% | – |
| EPS | -0.56 | -0.49 | -0.57 | -0.47 |
| % Growth | -14.3% | 14% | -21.3% | – |
| EPS Diluted | -0.56 | -0.49 | -0.57 | -0.47 |
| Weighted Avg Shares Out | 48 | 46 | 42 | 41 |
| Weighted Avg Shares Out Dil | 48 | 46 | 42 | 41 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$27 | -$22 | -$25 | -$21 |
| % Margin | – | – | -5,531.2% | – |